|
|
||||||||
in rats
Nephrology Research and Training Center, Comprehensive Cancer Center, and Cell Adhesion and Matrix Research Center, Division of Nephrology, Department of Medicine and Department of Physiology and Biophysics, University of Alabama at Birmingham, Birmingham 35294-0007; and Department of Veterans Affairs Medical Center, Birmingham, Alabama 35233
| |
ABSTRACT |
|---|
|
|
|---|
Transforming growth factors (TGF) are potent multifunctional
polypeptides that are involved in renal function and glomerular sclerosis. We postulated that dietary salt modified renal production of
TGF-
. An increase in dietary salt produced sustained increases in
steady-state levels of mRNA for TGF-
1, -
2, and -
3 in the rat
kidney. While serum concentration of TGF-
1 did not change, the 8.0%
NaCl diet increased urinary excretion of TGF-
1, indicating enhanced
renal production was the source of TGF-
1. Increasing urinary flow
rates with diuretics did not further increase synthesis of TGF-
1 in
animals receiving the 8.0% NaCl diet. The 8.0% NaCl diet increased
production of TGF-
1 in both glomeruli and tubules, although active
TGF-
1 was secreted in greater amounts only from glomeruli. Enhanced
glomerular production of both inactive and active TGF-
1 induced by
the 8.0% NaCl diet was inhibited by tetraethylammonium (TEA) and not
glybenclamide. Cardiac production of TGF-
1 also increased on the
8.0% NaCl diet but was not affected by TEA. The results demonstrated
that increased dietary salt augmented glomerular TGF-
production by
a mechanism that included a TEA-sensitive potassium channel. Dietary
salt, by facilitating glomerular expression of TGF-
, may directly
promote development of glomerulosclerosis.
glomerulus; potassium channel; sodium chloride
| |
INTRODUCTION |
|---|
|
|
|---|
TRANSFORMING GROWTH FACTOR (TGF) was a term used
initially by Roberts and associates (38) in 1980 to describe a
collection of polypeptides that could be extracted from almost any
normal tissue of the mouse. These peptides were functionally divided into TGF-
, which competed with epidermal growth factor (EGF) for
receptor binding and did not require EGF to promote growth of normal
rat kidney (NRK) cells in culture, and TGF-
, which did not compete
with EGF for receptor binding but did require EGF to stimulate growth
(7). TGF-
s are now known as a family of five multifunctional
polypeptides that have complex effects on organ development, cell
growth, and differentiation, expression of extracellular matrix
proteins, immune responses, angiogenesis, and tissue repair, as
reviewed in detail by Roberts and Sporn (39). Mammals produce TGF-
1,
-
2, and -
3 but not -
4 or -
5. The biological effects, which
are similar among the TGF-
s, depend upon the target cell, the degree
of cellular differentiation, and the cellular environment (37).
TGF-
s are synthesized in latent form and secreted as
disulfide-linked homodimers of ~100 kDa. Removal of the amino
terminus of latent TGF-
in the extracellular space forms a mature,
biologically active form of TGF-
that has a molecular weight of
~25 kDa (39). How this latent TGF-
complex is activated in vivo is
unclear, although acidification, protease treatment, and interaction
with thrombospondin have also been shown to activate TGF-
in vitro
(8, 39, 42-44). The complex structure and function of the kidney
make it a prime target for the action of a growth factor. TGF-
1 is
present in glomeruli and all nephron segments of normal rat kidney (6).
It is well accepted that angiotensin II modulates TGF-
(3, 20, 25,
28, 49). In apparent contradiction of these findings, however, was the
recent report (47) that demonstrated enhanced glomerular expression of
TGF-
in the Brookhaven strain of salt-sensitive rats, which have a
low-renin form of hypertension. Conclusions about the direct role of
dietary salt were not entertained in that study, because, at the time
of examination, the animals had severe hypertension and renal damage,
which provided additional modifying variables. In addition, time-course
experiments were omitted, and normotensive strains that did not have
renal failure were not included. We hypothesized that dietary salt
directly modulated expression of TGF-
through a mechanism
independent of the renin-angiotensin system. Using immunoassay and
Northern hybridization analysis, we document in the present study the
effect of dietary salt on the renal expression of TGF-
in
Sprague-Dawley rats.
| |
METHODS |
|---|
|
|
|---|
Animal preparation. Studies were
conducted on 56 male Sprague-Dawley rats obtained at 28 days of age
from Charles River Laboratories (Wilmington, MA). Animals were chosen
at this age because of our previous experience that showed normal renal
function and blood pressure responses to dietary salt over 2 wk of
observation (13). The rats were housed under standard conditions and
given 0.3% NaCl diet (AIN-76A with 0.3% NaCl; Dyets, Bethlehem, PA)
and water ad libitum for 4 days before initiating the experiment. This
diet contained sodium chloride in amounts similar to standard rat diet. The animals were then placed in metabolic cages and allowed free access
to water and rat diet, which contained either 0.3% (group termed
Lo-salt) or 8.0% (AIN-76A with 8.0% NaCl, Dyets) (group termed
Hi-salt) sodium chloride (n = 24 for each group). Animals received salt only in the diet. Urine
was collected under oil to prevent desiccation. Urine volume and body
weight were recorded daily. In other experiments, rats on 8.0% NaCl
diet received twice daily intraperitoneal injections of either
furosemide (5 mg/kg, denoted Hi-F; Elkins-Sinn, Cherry Hill, NJ) or
chlorothiazide (4 mg/kg, denoted Hi-C; Merck, West Point, PA)
(n = 4 in each group). Collected urine
samples from each rat were filtered and centrifuged at 325 g for 5 min at 4°C. The
supernatant was collected and immediately frozen and stored at
80°C until use. Rats were killed on days
1, 4, and
15. Both kidneys were harvested under aseptic conditions for glomerular and tubular cell culture and Northern
hybridization analysis, as described below. Blood was collected
simultaneously for determination of serum TGF-
1 and sodium
concentration. Plasma and urine samples were analyzed for sodium and
potassium using flame photometry (model IL-943; Instrumentation Laboratories, Lexington, MA).
Glomerular and tubular cell culture.
Glomerular and tubular cell preparations were isolated using a graded
sieving technique. This protocol has been shown to produce pure and
viable glomeruli for study of TGF-
(11, 27, 47, 48). Rats were
anesthetized with pentobarbital, 50 mg/kg, by intraperitoneal
injection. The kidneys were perfused in situ via the aorta with cold
isotonic heparinized saline until blanched (50-60 ml saline over 2 min). The renal cortices from each rat were individually dissected and minced to a pastelike consistency. The homogenate was passed
successively through a 106-µm metal sieve that excluded blood vessels
and a 75-µm nylon sieve that retained the glomeruli and allowed cells and small tubular segments to pass through. Glomeruli and tubules were
collected separately and washed three times with ice-cold PBS at 120 g for 2 min, then resuspended at 5 × 103 glomeruli or 1 × 106 tubular cells/ml of serum-free
RPMI 1640 (GIBCO; Life Technologies, Grand Island, NY).
All glomerular preparations consisted of more than 95% glomeruli with
minimal tubular contamination, as assessed visually at ×40
magnification. Some freshly collected samples of glomeruli were used to
obtain total RNA, as described below. In other experiments, samples of
glomeruli and tubules in 24-well plates were pretreated with
tetraethylammonium chloride (TEA, 3 mM; Sigma, St. Louis, MO) or
glybenclamide (10
5 M,
Sigma), in serum-free RPMI media at 37°C. Glybenclamide was dissolved in DMSO; final concentration of DMSO in the medium was 0.002%. TEA in this dose specifically inhibits potassium channels but
is relatively nonselective, whereas glybenclamide inhibits KATP channels (12, 15, 16, 34,
35); both compounds have been used specifically to examine TGF-
production by endothelial cells (34). Following a 30-min incubation
period, the medium was removed and replaced with serum-free media that
contained the same concentrations of TEA and glybenclamide. All samples were then incubated for 24 h at 37°C. In these same animals, the heart was also dissected and sectioned. Coronal slices of heart tissue
were weighed in a petri dish, then minced with a scalpel into small
pieces <1 mm in diameter. The sections were rinsed with cold PBS and
suspended in serum-free RPMI 1640 at a concentration of 10 mg
tissue/ml. After incubation for 24 h, samples of conditioned media were
harvested. Phenylmethylsulfonyl fluoride (1 mM, Sigma) was added as a
protease inhibitor, and the mixture was centrifuged at 200 g for 5 min at 4°C. The pellet was
dissolved in RIPA buffer (50 mM Tris hydrochloride, 150 mM NaCl, 1 mM
disodium EDTA, 0.1 mM EGTA, 1.0% Nonidet P-40, 0.1% SDS,
0.5% sodium deoxycholate) for protein assay (Micro BCA protein assay
reagent kit; Pierce, Rockford, IL), and the supernatant was collected
and stored at
20°C until assay.
TGF-
1 assay. Total
TGF-
1 in rat urine, serum, and conditioned media was determined
using an enzyme immunoassay (TGF-
1
Emax ImmunoAssay System; Promega,
Madison, WI), following the protocol provided by the manufacturer.
Briefly, plates containing 96 flat-bottom wells (Falcon;
Becton-Dickinson, Oxnard, CA) were coated overnight at 4°C with 100 µl of anti-TGF-
1 monoclonal antibody diluted 1:1,000 in buffer
that contained 0.025 M sodium bicarbonate and 0.025 M sodium carbonate,
pH 9.7. Thereafter, unbound sites in the wells were blocked, using 270 µl of the blocking reagent supplied in the kit for 2 h at room
temperature, then 100 µl of the test samples or TGF-
1 standard
diluted in sample buffer was added to wells. Following incubation for 3 h at room temperature with vigorous shaking, the wells were washed five
times with TBST wash buffer (20 mM Tris · HCl, pH
7.6, 150 mM NaCl, and 0.05% Tween-20), then 100 µl of polyclonal
anti-TGF-
1 diluted in sample buffer was added. The plates were again
incubated overnight at 4°C. After five washes with TBST buffer,
wells were filled with 100 µl of antibody conjugated with horseradish
peroxidase and incubated for 3 h at room temperature with shaking.
Following additional washes as in the previous steps, color was
developed by adding 100 µl of peroxidase substrate in
3,3',S,S'-tetramethyl benzidine solution. After ~10-min incubation at room temperature,
100 µl of 1 M phosphoric acid were added to stop the color reaction. Optical density was determined at 450 nm using a microplate reader (THERMOmax; Molecular Devices,
Menlo Park, CA). Standards were performed in duplicate using TGF-
1,
7.8-1,000 pg/ml in sample buffer, and were used to construct
standard curves from which the concentrations of the samples were
determined. Urine samples from animals on the 0.3% NaCl diet were
diluted 1:1 in sample buffer, and urine samples from animals on 8.0%
NaCl diet were not diluted. Serum samples were diluted 1:50 in sample
buffer for this assay. Because this assay detected only active
TGF-
1, some samples of media were also acidified to convert latent
TGF-
1 to the active from. This protocol was provided by the
manufacturer and briefly consisted of acidifying 100 µl of sample to
pH 3.2 by addition of 2 µl of 1 N HCl for 30 min at room temperature. The transiently acidified samples were then brought to pH 7.4 with 2 µl of 1 N NaOH. Assay then proceeded as described above and
allowed determination of total (latent plus active) TGF-
1 in the
sample.
Northern hybridization. Total RNA was
isolated by single-step method of acid guanidinium thiocyanate-phenol
chloroform extraction (14). Briefly, kidneys were homogenized in a
denaturing solution of 4 M guanidinium isothiocyanate, 0.5% sarcosyl,
and 0.1 M
-mercaptoethanol in 25 mM sodium citrate (pH 7.0). After
phenol/chloroform extraction, the RNA was precipitated twice with
isopropanol and washed with 70% ethanol. The concentration and purity
of RNA in each sample were determined using optical density at 260 and
280 nm. Thirty micrograms of total RNA from each sample were
electrophoresed in 1.5% agarose gels containing 2.2 M formaldehyde and
0.2 M MOPS, pH 7.0, then transferred to a nylon membrane (GeneScreen
Plus Hybridization Transfer Membrane; NEN Life Science Products,
Boston, MA) by vacuum blotting (model 785; Bio-Rad, Hercules, CA) for 2 h in 10× SSC (1× SSC is 0.15 M NaCl and 0.015 M sodium
citrate, pH 7.0). Nucleic acids were cross-linked by ultraviolet
irradiation (Stratagene, La Jolla, CA). The membranes were
prehybridized for 20 min at 68°C in standard hybridization solution
(QuikHyb; Stratagene). They were then hybridized at 68°C for 4 h
with cDNA probes for rat TGF-
1 and murine TGF-
2 and TGF-
3 (all
kindly provided by Dr. Thomas S. Winokur, University of Alabama at
Birmingham). The cDNA probes, which consisted of ~1-kb fragments
produced by digestion of the plasmids with
Hind III and
Xba I and included the entire coding
region of the TGF-
s (19), were labeled with
[
-32P]dCTP
by random oligonucleotide priming (Prime-a-Gene Labeling system;
Promega). The blots were washed in 2× SSC with 0.1% SDS at room
temperature for 30 min and in 0.1× SSC with 0.1% SDS at 60°C
for 20-30 min. Membranes were exposed to XAR-5 film (Kodak) at
80°C. The blots were then stripped in solution containing 1 mM Tris · HCl, pH 8.0, 0.1 mM EDTA, and 0.1×
Denhardt's solution, at 75°C for 2 h and rehybridized with human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe obtained through
American Type Culture Collection (Rockville, MD). Autoradiographs were
scanned using a densitometry (model 620 Video Densitometer, Bio-Rad).
The density of the GAPDH band in the same lane was used to normalize
mRNA loading. For quantification, densities of the bands of TGF-
s were individually divided by the density of band for GAPDH in the same
lane.
Statistical analysis. All data are presented as means ± SE. Significant difference among data sets was determined using either unpaired t-test or one-way analysis of variance with standard post hoc testing (Statview, version 4.5; Abacus Concepts, Berkeley, CA), where appropriate. Simple regression (Statview) was used to determine the relationship between dependent and independent variables. A value of 5% was used to assign statistical significance.
| |
RESULTS |
|---|
|
|
|---|
Mean body weights, serum Na+ concentration, urinary flow rate, urinary sodium excretion rate, and urinary potassium excretion rate are shown in Table 1. One animal in the Lo-salt group died of unexplained causes. As expected, urinary flow rate and urinary sodium and potassium excretion rates of the Lo-salt groups were less (P < 0.05) than the corresponding Hi-salt groups. Mean body weight of the Lo-salt group on the diet for 4 days was less (P < 0.05) than the corresponding Hi-salt group.
|
Mean serum concentrations of TGF-
1 did not change during salt
loading or with addition of furosemide or chlorothiazide (Tables 2 and 3). In marked contrast, urinary
excretion of total TGF-
1 was much higher than in rats on the 8.0%
NaCl diet. The effect of dietary salt occurred by the first day and
persisted throughout the 15 days of study. Urinary excretion of
TGF-
1 correlated
(r2 = 0.561;
P < 0.0001) directly with urinary
sodium excretion rates. Both of the diuretics increased urinary flow
but did not produce further increases in excretion of TGF-
1. In
these experiments, urinary excretion of TGF-
1 did not correlate with
urine flow rate
(r2 = 0.052;
P = 0.3356).
|
Mean steady-state levels of mRNA of TGF-
1, TGF-
2, and TGF-
3 in
the kidney were also greater (P < 0.05) than mRNA levels of these growth factors in animals on 0.3% NaCl
diet (Figs. 1 and
2; Tables 2 and
3). Steady-state levels of mRNA correlated (r2 = 0.374;
P < 0.0001) directly with urinary
excretion of total TGF-
1. Freshly isolated glomeruli from rats
receiving the 8.0% NaCl diet for 4 days also had a higher content of
TGF-
1 mRNA than rats receiving the 0.3% NaCl diet (Fig.
3). Furosemide produced further increases
(P < 0.05) in mRNA of
TGF-
3, but not TGF-
1 or TGF-
2, compared with animals on the
8.0% NaCl diet alone (Table 3).
|
|
|
|
Production of total (latent plus active), as well as active, TGF-
1
was examined in glomerular and cortical tubular cell preparations from
rats on the 8.0% NaCl and 0.3% NaCl diets
(n = 4 animals in each group).
Secretion of total TGF-
1 was increased
(P < 0.05) in both preparations
obtained from animals on the 8.0% NaCl diet, but secretion of active
TGF-
1 was increased only in glomeruli from the Hi-salt group (Fig.
4). To determine whether potassium channels
were involved in TGF-
production, we followed the protocol of Ohno
and associates (34), who used TEA and glybenclamide to examine
TGF-
1 production in endothelial cells in culture. Addition of TEA to
the medium reduced active and total TGF-
1 to levels comparable to
those produced by glomeruli obtained from the Lo-salt group (Fig. 4);
TEA had no effect on TGF-
1 production by tubular cells.
Glybenclamide had no effect on TGF-
1 production by either
preparation. Total TGF-
1 production by cardiac tissue from the
Hi-salt group was greater (760 ± 46 vs. 563 ± 91 fg · h
1 · mg
protein
1;
P < 0.05) than that
secreted by cardiac tissue from the Lo-salt group. TEA did not alter
production of TGF-
1 by cardiac tissue from the Hi-salt or Lo-salt
groups (Hi-salt, 760 ± 46 vs. 689 ± 37; Lo-salt, 563 ± 91 vs. 650 ± 75 fg · h
1 · mg
protein
1).
|
| |
DISCUSSION |
|---|
|
|
|---|
TGF-
s are multifunctional growth factors that play an important role
in kidney growth, development, and senescence (2, 9, 10, 24, 33, 39,
41, 48, 50-52). Expressions of TGF-
1, -
2, and -
3 have
been identified in both glomeruli and tubules (6, 7, 39, 40, 51, 53,
54). A majority of studies have focused on expression of these growth
factors in developmental and pathological states in the kidney, but
recent evidence supports a functional role of TGF-
in adult animals, including tubular cell hypertrophy and proliferation, stimulation of
adenylyl cyclase, and inhibition of cathepsin production (4, 5, 30,
40). In the current studies, we examined the potential role of dietary
salt in modifying growth factor expression in the kidney. Physiological
adaptation of TGF-
expression to dietary salt has not been examined
but is an important consideration, particularly in pathological states
that produce glomerulosclerosis. Our current findings showed that an
increase in dietary salt produced sustained increases in steady-state
levels of mRNA of TGF-
1, -
2, and -
3 in the kidney, compared
with rats that received a diet that was identical in composition except
for the lower content of sodium chloride. While serum concentrations of
TGF-
1 did not change, the 8.0% NaCl diet increased urinary
excretion of TGF-
1. Thus the kidney was the source of augmented
excretion of TGF-
1. Diuretics (furosemide or chlorothiazide), which
were added to the 8.0% NaCl diets in part to determine whether
increasing urinary flow rates modulated TGF-
, did not further
augment synthesis of TGF-
1. Production of TGF-
1 increased in both
glomeruli and tubules, although the active form of TGF-
1 was
secreted in greater amounts only from glomeruli. Enhanced glomerular
production of both inactive and active TGF-
1 induced by the 8.0%
NaCl diet was inhibited by addition of TEA and not glybenclamide.
Dietary salt therefore appeared to activate a TEA-sensitive potassium channel that in turn increased glomerular production of TGF-
1.
As reviewed in detail by Davies (17), blood coursing through a vessel
produces shear stress, a frictional force that directly alters
endothelial cell function. An early event in this process is opening of a shear-activated potassium channel (36), which hyperpolarizes the endothelium and increases cytoplasmic calcium (16,
32, 45). Ohno and associates (34) demonstrated shear-induced expression
of TGF-
1 in endothelial cells in culture. Blockade of the
shear-activated potassium channel with TEA, 3 mM, but not glybenclamide, 10
5 M,
produced dramatic reductions in gene transcription and protein activity
of TGF-
1 (34). Our current studies showed this effect occurs in
vivo, specifically in glomeruli and not in tubular cells or in the
heart. We propose that an increase in dietary salt, by increasing blood
volume (18), produced shear stress in glomeruli and increased
expression of TGF-
1 specifically in that region of the nephron.
Augmented expression of TGF-
1 in the tubules and heart was modest
and occurred by a different mechanism that was not defined in this
study. We suggest that because active TGF-
1, but not the latent
form, is a low-molecular-weight protein, significant amounts of the
active form can appear in glomerular ultrafiltrate and subsequently
interact with proximal tubular cells to promote cell growth and
hypertrophy (5, 22, 30, 40) and stimulate autocrine production of
TGF-
, which has been demonstrated to occur in cells in culture (1,
26).
In conclusion, to the extent that our work can be applied in vivo,
although angiotensin II stimulates renal production of TGF-
(3, 25,
49), dietary salt increases TGF-
not through the renin-angiotensin
system but instead by a mechanism that involves alteration of shear
stress in glomeruli and activation of a TEA-sensitive potassium
channel. The role(s) of this growth factor in the renal adaptation to
dietary salt is uncertain, although TGF-
may alter NO production,
which in turn modulates glomerular hemodynamics, glomerular filtration
rate, and renin secretion (23, 31, 46). Finally, a pathogenic role of
TGF-
in glomerulosclerosis has been described (2, 21, 24, 29, 50,
51, 54). One recent report showed increased expression of TGF-
in
isolated glomeruli from Dahl salt-sensitive rats that had been made
hypertensive by a 4-wk treatment with an 8.0% NaCl diet. These animals
demonstrated marked nephrosclerosis (47). Although a time course was
not performed and control animals that maintained a normal blood
pressure and did not manifest nephrosclerosis on the 8.0% NaCl diet
were not examined in that study, by directly modifying TGF-
expression in glomeruli, the role dietary salt may play in facilitating
glomerulosclerosis through a shear stress-related mechanism should be
entertained.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Thomas S. Winokur, University of Alabama at Birmingham, for helpful discussions, and the Media Service of the Birmingham Veterans Affairs Medical Center, for the photography.
| |
FOOTNOTES |
|---|
This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-46199 and by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs.
Address for reprint requests: P. W. Sanders, Division of Nephrology/Dept. of Medicine, 642 Lyons-Harrison Research Bldg., Univ. of Alabama at Birmingham, Birmingham, AL 35294-0007.
Received 18 August 1997; accepted in final form 19 November 1997.
| |
REFERENCES |
|---|
|
|
|---|
1.
Agrotis, A.,
J. Saltis,
and
A. Bobik.
Transforming growth factor-
1 gene activation and growth of smooth muscle from hypertensive rats.
Hypertension
23:
593-599,
1994
2.
Akagi, Y.,
Y. Isaka,
M. Arai,
T. Kaneko,
M. Takenaka,
T. Moriyama,
Y. Kaneda,
A. Ando,
Y. Orita,
T. Kamada,
N. Ueda,
and
E. Imai.
Inhibition of TGF-
1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis.
Kidney Int.
50:
148-155,
1996[Medline].
3.
Anderson, P. W.,
X. Y. Zhang,
J. Tian,
J. D. Correale,
X. P. Xi,
D. Yang,
K. Graf,
R. E. Law,
and
W. A. Hsueh.
Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells.
Kidney Int.
50:
745-753,
1996[Medline].
4.
Anderson, R. J.,
H. T. Sponsel,
R. Breckon,
T. Marcell,
and
J. P. Hoeffler.
Transforming growth factor-
1 regulation of signal transduction in two renal epithelial cell lines.
Am. J. Physiol.
265 (Renal Fluid Electrolyte Physiol. 34):
F584-F591,
1993
5.
Anderson, R. J.,
H. T. Sponsel,
D. J. Kroll,
S. Jackson,
R. Breckon,
and
J. P. Hoeffler.
Escape from the antiproliferative effect of transforming growth factor-
1 in LLC-PK1 renal epithelial cells.
Kidney Int.
45:
642-649,
1994[Medline].
6.
Ando, T.,
S. Okuda,
K. Tamaki,
K. Yoshitomi,
and
M. Fujishima.
Localization of transforming growth factor-
and latent transforming growth factor-
binding protein in rat kidney.
Kidney Int.
47:
733-739,
1995[Medline].
7.
Anzano, M. A.,
A. B. Roberts,
C. A. Meyers,
A. Komoriya,
L. C. Lamb,
J. M. Smith,
and
M. B. Sporn.
Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells.
Cancer Res.
42:
4776-4778,
1982
8.
Blanchette, F.,
R. Day,
W. Dong,
M.-H. Laprise,
and
C. M. Dubois.
TGF
1 regulates gene expression of its own converting enzyme furin.
J. Clin. Invest.
99:
1974-1983,
1997[Medline].
9.
Border, W. A.,
N. A. Noble,
T. Yamamoto,
J. R. Harper,
Y. Yamaguchi,
M. D. Pierschbacher,
and
E. Ruoslahti.
Natural inhibitor of transforming growth factor-
protects against scarring in experimental kidney disease.
Nature
360:
361-364,
1992[Medline].
10.
Border, W. A.,
S. Okuda,
L. R. Languino,
M. B. Sporn,
and
E. Ruoslahti.
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor
1.
Nature
346:
371-374,
1990[Medline].
11.
Cattell, V.,
T. Cook,
and
S. Moncada.
Glomeruli synthesize nitrite in experimental nephrotoxic nephritis.
Kidney Int.
38:
1056-1060,
1990[Medline].
12.
Chen, G.,
and
D. W. Cheung.
Characterization of acetylcholine-induced membrane hyperpolarization in endothelial cells.
Circ. Res.
70:
257-263,
1992
13.
Chen, P. Y.,
and
P. W. Sanders.
L-Arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats.
J. Clin. Invest.
88:
1559-1567,
1991.
14.
Chomczynski, P.,
and
N. Sacchi.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:
156-159,
1987[Medline].
15.
Cook, N. S.
The pharmacology of potassium channels and their therapeutic potential.
Trends Pharmacol. Sci.
9:
21-28,
1988[Medline].
16.
Cooke, J. P.,
E. Rossitch, Jr.,
N. A. Andon,
J. Loscalzo,
and
V. J. Dzau.
Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator.
J. Clin. Invest.
88:
1663-1671,
1991.
17.
Davies, P. F.
Flow-mediated endothelial mechanotransduction.
Physiol. Rev.
75:
519-560,
1995
18.
Davis, J. M.,
D. A. Häberle,
and
T. Kawata.
The control of glomerular filtration rate and renal blood flow in chronically volume-expanded rats.
J. Physiol. (Lond.)
402:
473-495,
1988
19.
Flanders, K. C.,
T. S. Winokur,
M. G. Holder,
and
M. B. Sporn.
Hyperthermia induces expression of transforming growth factor-
s in rat cardiac cells in vitro and in vivo.
J. Clin. Invest.
92:
404-410,
1993.
20.
Gibbons, G. H.,
R. E. Pratt,
and
V. J. Dzau.
Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-
1 expression determines growth response to angiotensin II.
J. Clin. Invest.
90:
456-461,
1992.
21.
Herrera, G. A.,
J. J. Shultz,
S.-j. Soong,
and
P. W. Sanders.
Growth factors in monoclonal light chain-related renal diseases.
Hum. Pathol.
25:
883-892,
1994[Medline].
22.
Humes, H. D.,
T. F. Beales,
D. A. Cieslinski,
I. O. Sanchez,
and
T. P. Page.
Effects of transforming growth factor-
, transforming growth factor-
, and other growth factors on renal proximal tubule cells.
Lab. Invest.
64:
538-545,
1991[Medline].
23.
Ikenaga, H.,
H. Suzuki,
N. Ishii,
H. Itoh,
and
T. Saruta.
Role of NO on pressure-natriuresis in Wistar-Kyoto and spontaneously hypertensive rats.
Kidney Int.
43:
205-211,
1993[Medline].
24.
Isaka, Y.,
Y. Fujiwara,
N. Ueda,
Y. Kaneda,
T. Kamada,
and
E. Imai.
Glomerulosclerosis induced by in vivo transfection of transforming growth factor-
or platelet-derived growth factor gene into the rat kidney.
J. Clin. Invest.
92:
2597-2601,
1993.
25.
Kagami, S.,
W. A. Border,
D. E. Miller,
and
N. A. Noble.
Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-
expression in rat glomerular mesangial cells.
J. Clin. Invest.
93:
2431-2437,
1994.
26.
Kaname, S.,
S. Uchida,
E. Ogata,
and
K. Kurokawa.
Autocrine secretion of transforming growth factor-
in cultured rat mesangial cells.
Kidney Int.
42:
1319-1327,
1992[Medline].
27.
Kitamura, M.,
T. Sütö,
T. Yokoo,
F. Shimizu,
and
L. G. Fine.
Transforming growth factor-
1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells.
J. Immunol.
156:
2964-2971,
1996[Abstract].
28.
Koibuchi, Y.,
W. S. Lee,
G. H. Gibbons,
and
R. E. Pratt.
Role of transforming growth factor-
1 in the cellular growth response to angiotensin II.
Hypertension
21:
1046-1050,
1993
29.
Lee, L. K.,
T. W. Meyer,
A. S. Pollock,
and
D. H. Lovett.
Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney.
J. Clin. Invest.
96:
953-964,
1995.
30.
Ling, H.,
S. Vamvakas,
G. Busch,
J. Dämmrich,
L. Schramm,
F. Lang,
and
A. Heidland.
Suppressing role of transforming growth factor-
1 on cathepsin activity in cultured kidney tubule cells.
Am. J. Physiol.
269 (Renal Fluid Electrolyte Physiol. 38):
F911-F917,
1995
31.
Majid, D. S. A.,
A. Williams,
P. J. Kadowitz,
and
L. G. Navar.
Renal responses to intra-arterial administration of nitric oxide donor in dogs.
Hypertension
22:
535-541,
1993
32.
Mo, M.,
S. G. Eskin,
and
W. P. Schilling.
Flow-induced changes in Ca2+ signaling of vascular endothelial cells: effect of shear stress and ATP.
Am. J. Physiol.
260 (Heart Circ. Physiol. 29):
H1698-H1707,
1991
33.
Nakamura, T.,
D. Miller,
E. Ruoslahti,
and
W. A. Border.
Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-
1.
Kidney Int.
41:
1213-1221,
1992[Medline].
34.
Ohno, M.,
J. P. Cooke,
V. J. Dzau,
and
G. H. Gibbons.
Fluid shear stress induces endothelial transforming growth factor beta-1 transcription and production.
J. Clin. Invest.
95:
1363-1369,
1995.
35.
Ohno, M.,
G. H. Gibbons,
V. J. Dzau,
and
J. P. Cooke.
Shear stress elevates endothelial cGMP: role of a potassium channel and G protein coupling.
Circulation
88:
193-197,
1993
36.
Olesen, S.-P.,
D. E. Clapham,
and
P. F. Davies.
Haemodynamic shear stress activates a K+ current in vascular endothelial cells.
Nature
331:
168-170,
1988[Medline].
37.
Roberts, A. B.,
M. A. Anzano,
L. M. Wakefield,
N. S. Roche,
D. F. Stern,
and
M. B. Sporn.
Type
transforming growth factor: a bifunctional regulator of cellular growth.
Proc. Natl. Acad. Sci. USA
82:
119-123,
1985
38.
Roberts, A. B.,
L. C. Lamb,
D. L. Newton,
M. B. Sporn,
J. E. De Larco,
and
G. J. Todaro.
Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction.
Proc. Natl. Acad. Sci. USA
77:
3494-3498,
1980
39.
Roberts, A. B.,
and
M. B. Sporn.
Transforming growth factor
.
Adv. Cancer Res.
51:
107-145,
1988[Medline].
40.
Rocco, M. V.,
Y. Chen,
S. Goldfarb,
and
F. N. Ziyadeh.
Elevated glucose stimulates TGF-
gene expression and bioactivity in proximal tubule.
Kidney Int.
41:
107-114,
1992[Medline].
41.
Rogers, S. A.,
G. Ryan,
A. F. Purchio,
and
M. R. Hammerman.
Metanephric transforming growth factor-
1 regulates nephrogenesis in vitro.
Am. J. Physiol.
264 (Renal Fluid Electrolyte Physiol. 33):
F996-F1002,
1993
42.
Schultz-Cherry, S.,
H. Chen,
D. F. Mosher,
T. M. Misenheimer,
H. C. Krutzsch,
D. D. Roberts,
and
J. E. Murphy-Ullrich.
Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1.
J. Biol. Chem.
270:
7304-7310,
1995
43.
Schultz-Cherry, S.,
J. Lawler,
and
J. E. Murphy-Ullrich.
The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta.
J. Biol. Chem.
269:
26783-26788,
1994
44.
Schultz-Cherry, S.,
S. Ribeiro,
L. Gentry,
and
J. E. Murphy-Ullrich.
Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system.
J. Biol. Chem.
269:
26775-26782,
1994
45.
Shen, J.,
F. W. Luscinskas,
A. Connolly,
C. F. Dewey, Jr.,
and
M. A. Gimbrone, Jr.
Fluid shear stress modulates cytosolic free calcium in vascular endothelial cells.
Am. J. Physiol.
262 (Cell Physiol. 31):
C384-C390,
1992
46.
Singh, I.,
M. Grams,
W.-H. Wang,
T. Yang,
P. Killen,
A. Smart,
J. Schnermann,
and
J. P. Briggs.
Coordinate regulation of renal expression of nitric oxide synthase, renin, and angiotensinogen mRNA by dietary salt.
Am. J. Physiol.
270 (Renal Fluid Electrolyte Physiol. 39):
F1027-F1037,
1996
47.
Tamaki, K.,
S. Okuda,
M. Nakayama,
T. Yanagida,
and
M. Fujishima.
Transforming growth factor-
1 in hypertensive renal injury in Dahl salt-sensitive rats.
J. Am. Soc. Nephrol.
7:
2578-2589,
1996[Abstract].
48.
Tomooka, S.,
W. A. Border,
B. C. Marshall,
and
N. A. Noble.
Glomerular matrix accumulation is linked to inhibition of the plasmin protease system.
Kidney Int.
42:
1462-1469,
1992[Medline].
49.
Van Det, N. F.,
J. T. Tamsma,
J. van den Born,
N. A. Verhagen,
L. P. van den Heuvel,
C. W. Lowik,
J. H. Berden,
J. A. Bruijn,
M. R. Daha,
and
F. J. van der Woude.
Differential effects of angiotensin II and transforming growth factor beta on the production of heparan sulfate proteoglycan by mesangial cells in vitro.
J. Am. Soc. Nephrol.
7:
1015-1023,
1996[Abstract].
50.
Yamamoto, T.,
T. Nakamura,
N. A. Noble,
E. Ruoslahti,
and
W. A. Border.
Expression of transforming growth factor
is elevated in human and experimental diabetic nephropathy.
Proc. Natl. Acad. Sci. USA
90:
1814-1818,
1993
51.
Yamamoto, T.,
N. A. Noble,
A. H. Cohen,
C. C. Nast,
A. Hishida,
L. I. Gold,
and
W. A. Border.
Expression of transforming growth factor-
isoforms in human glomerular diseases.
Kidney Int.
49:
461-469,
1996[Medline].
52.
Yamamoto, T.,
N. A. Noble,
D. E. Miller,
and
W. A. Border.
Sustained expression of TGF-
1 underlies development of progressive kidney fibrosis.
Kidney Int.
45:
916-927,
1994[Medline].
53.
Yoshioka, K.,
T. Takemura,
K. Murakami,
M. Okada,
S. Hino,
H. Miyamoto,
and
S. Maki.
Transforming growth factor-
protein and mRNA in glomeruli in normal and diseased human kidneys.
Lab. Invest.
68:
154-163,
1993[Medline].
54.
Zhu, L.,
G. A. Herrera,
J. E. Murphy-Ullrich,
Z.-Q. Huang,
and
P. W. Sanders.
Pathogenesis of glomerulosclerosis in light chain deposition disease: role for transforming growth factor-
.
Am. J. Pathol.
147:
375-385,
1995[Abstract].
This article has been cited by other articles:
![]() |
W.-Z. Ying, K. Aaron, and P. W. Sanders Mechanism of dietary salt-mediated increase in intravascular production of TGF-{beta}1 Am J Physiol Renal Physiol, August 1, 2008; 295(2): F406 - F414. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Spurgeon-Pechman, D. L. Donohoe, D. L. Mattson, H. Lund, L. James, and D. P. Basile Recovery from acute renal failure predisposes hypertension and secondary renal disease in response to elevated sodium Am J Physiol Renal Physiol, July 1, 2007; 293(1): F269 - F278. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-Z. Ying and P. W. Sanders Enhanced expression of EGF receptor in a model of salt-sensitive hypertension Am J Physiol Renal Physiol, August 1, 2005; 289(2): F314 - F321. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-X. Wang and P. W. Sanders Mechanism of hypertensive nephropathy in the Dahl/Rapp rat: a primary disorder of vascular smooth muscle Am J Physiol Renal Physiol, January 1, 2005; 288(1): F236 - F242. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-Z. Ying and P. W. Sanders The interrelationship between TGF-{beta}1 and nitric oxide is altered in salt-sensitive hypertension Am J Physiol Renal Physiol, November 1, 2003; 285(5): F902 - F908. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Dahly, K. M. Hoagland, A. K. Flasch, S. Jha, S. R. Ledbetter, and R. J. Roman Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2002; 283(3): R757 - R767. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Husted, R. D. Sigmund, and J. B. Stokes Mechanisms of inactivation of the action of aldosterone on collecting duct by TGF-beta Am J Physiol Renal Physiol, March 1, 2000; 278(3): F425 - F433. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-Z. Ying and P. W. Sanders Dietary salt increases endothelial nitric oxide synthase and TGF-beta 1 in rat aortic endothelium Am J Physiol Heart Circ Physiol, October 1, 1999; 277(4): H1293 - H1298. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-Z. Ying and P. W. Sanders Dietary salt enhances glomerular endothelial nitric oxide synthase through TGF-beta 1 Am J Physiol Renal Physiol, July 1, 1998; 275(1): F18 - F24. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-Z. Ying, H. Xia, and P. W. Sanders Nitric Oxide Synthase (NOS2) Mutation in Dahl/Rapp Rats Decreases Enzyme Stability Circ. Res., August 17, 2001; 89(4): 317 - 322. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE |